MX367970B - Combination therapies for melanoma comprising administering cobimetinib and vemurafinib. - Google Patents

Combination therapies for melanoma comprising administering cobimetinib and vemurafinib.

Info

Publication number
MX367970B
MX367970B MX2015002031A MX2015002031A MX367970B MX 367970 B MX367970 B MX 367970B MX 2015002031 A MX2015002031 A MX 2015002031A MX 2015002031 A MX2015002031 A MX 2015002031A MX 367970 B MX367970 B MX 367970B
Authority
MX
Mexico
Prior art keywords
melanoma
vemurafinib
combination therapies
cobimetinib
relates
Prior art date
Application number
MX2015002031A
Other languages
Spanish (es)
Other versions
MX2015002031A (en
Inventor
Gordon Bray
Iris T Chan
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49035547&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367970(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2015002031A publication Critical patent/MX2015002031A/en
Publication of MX367970B publication Critical patent/MX367970B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06Q—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL OR SUPERVISORY PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00—Commerce
    • G06Q30/02—Marketing; Price estimation or determination; Fundraising
    • G06Q30/0241—Advertisements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Abstract

The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. Even more specifically, the invention relates to compositions comprising cobimetinib and vemurafenib and their use in the treatment of BRAF-V600 mutation-positive unresectable or metastatic melanoma.
MX2015002031A 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib. MX367970B (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261684673P 2012-08-17 2012-08-17
US201261705575P 2012-09-25 2012-09-25
US201261706026P 2012-09-26 2012-09-26
US201261722725P 2012-11-05 2012-11-05
US201361780708P 2013-03-13 2013-03-13
PCT/EP2013/067050 WO2014027056A1 (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib

Publications (2)

Publication Number Publication Date
MX2015002031A MX2015002031A (en) 2015-06-05
MX367970B true MX367970B (en) 2019-09-11

Family

ID=49035547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002031A MX367970B (en) 2012-08-17 2013-08-15 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib.

Country Status (31)

Country Link
US (3) US11087354B2 (en)
EP (1) EP2884979B1 (en)
JP (2) JP6335169B2 (en)
KR (5) KR20210108502A (en)
CN (2) CN104640545A (en)
AU (1) AU2013304021B2 (en)
BR (1) BR112015003418A2 (en)
CA (2) CA2928396A1 (en)
CL (1) CL2015000345A1 (en)
CO (1) CO7180225A2 (en)
DK (1) DK2884979T3 (en)
EA (1) EA033573B1 (en)
ES (1) ES2743427T3 (en)
HK (1) HK1206605A1 (en)
HR (1) HRP20191533T1 (en)
HU (1) HUE044789T2 (en)
IL (1) IL237065B (en)
LT (1) LT2884979T (en)
MX (1) MX367970B (en)
MY (1) MY180613A (en)
NZ (1) NZ744862A (en)
PE (1) PE20151156A1 (en)
PH (1) PH12015500186A1 (en)
PL (1) PL2884979T3 (en)
PT (1) PT2884979T (en)
RS (1) RS59113B1 (en)
SG (3) SG10201913359TA (en)
SI (1) SI2884979T1 (en)
UA (1) UA114923C2 (en)
WO (1) WO2014027056A1 (en)
ZA (1) ZA201500348B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210108502A (en) * 2012-08-17 2021-09-02 에프. 호프만-라 로슈 아게 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
US9532987B2 (en) 2013-09-05 2017-01-03 Genentech, Inc. Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
CN107073121A (en) * 2014-06-13 2017-08-18 基因泰克公司 Treatment and the method for prevention cancer drug resistance
CZ2015250A3 (en) * 2015-04-14 2016-10-26 Zentiva, K.S. Vemurafenib amorphous forms
JP2018515570A (en) * 2015-05-22 2018-06-14 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． PLX-8394 or PLX-7904 for use in the treatment of BRAF-V600 related diseases
SI3881833T1 (en) * 2015-06-30 2024-03-29 Genentech, Inc., Immediate-release tablets containing a drug and processes for forming the tablets
US10959993B2 (en) 2015-11-03 2021-03-30 Genentech, Inc. Combination of Bcl-2 inhibitor and MEK inhibitor for the treatment of cancer
PL3377107T3 (en) * 2015-11-19 2020-12-14 F. Hoffmann-La Roche Ag Methods of treating cancer using b-raf inhibitors and immune checkpoint inhibitors
US20180369195A1 (en) * 2015-11-30 2018-12-27 The Regents Of The University Of California Combination therapy for treatment of melanoma
MX2019001635A (en) 2016-08-12 2019-06-10 Genentech Inc Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a vegf inhibitor.
BR112019005815A2 (en) 2016-09-29 2019-06-25 Genentech Inc methods of treating an individual with breast cancer, breast cancer treatment kit, and breast cancer therapy drug combination
ES2928773T3 (en) 2017-01-17 2022-11-22 Heparegenix Gmbh Protein kinase inhibitors to promote liver regeneration or reduce or prevent hepatocyte death
US11077189B2 (en) 2017-03-02 2021-08-03 Genentech Inc. Adjuvant treatment of HER2-positive breast cancer
US11395823B2 (en) 2018-01-09 2022-07-26 Duke University Topical administration of MEK inhibiting agents for the treatment of skin disorders
CN109879855B (en) * 2019-03-26 2021-01-05 中国医学科学院医药生物技术研究所 Inhibitor targeting PD-L1 molecule on surface of tumor cell and application thereof
EP4149472A1 (en) * 2020-05-12 2023-03-22 Novartis AG Therapeutic combinations comprising a craf inhibitor
KR20230156731A (en) 2021-03-09 2023-11-14 제넨테크, 인크. Belvarafenib for use in the treatment of brain cancer
JP2024514112A (en) 2021-04-06 2024-03-28 ジェネンテック， インコーポレイテッド Combination therapy with bervarafenib and cobimetinib or combination therapy with bervarafenib, cobimetinib and atezolizumab

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005526008A (en) 2001-12-04 2005-09-02 オニックス ファーマシューティカルズ，インコーポレイティド RAF-MEK-ERK pathway inhibitors for treating cancer
SI1482932T1 (en) 2002-03-13 2010-02-26 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AU2003286447A1 (en) 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
AU2004293436B2 (en) 2003-11-19 2010-12-09 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7732616B2 (en) 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
US7517994B2 (en) 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
EP1696920B8 (en) 2003-12-19 2015-05-06 Plexxikon Inc. Compounds and methods for development of ret modulators
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
EP3088400A1 (en) 2005-06-22 2016-11-02 Plexxikon Inc. Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors
DK1913157T4 (en) 2005-06-28 2017-01-23 Genentech Inc EGFR and KRAS mutations for predicting patient response to EGFR inhibitor therapy.
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US9095581B2 (en) 2005-07-21 2015-08-04 Ardea Biosciences, Inc. Combinations of MEK inhibitors and Raf kinase inhibitors and uses thereof
US7713960B2 (en) 2005-07-22 2010-05-11 University Of South Florida Inhibition of the Raf/Mek/P-Erk pathway for treating cancer
CA3052368A1 (en) 2005-10-07 2007-04-19 Exelixis, Inc. Azetidines as mek inhibitors
GEP20125701B (en) * 2006-09-13 2012-12-10 Takeda Pharmaceuticals Co Application of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
SG174826A1 (en) 2006-09-19 2011-10-28 Novartis Ag Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors
CN105106199A (en) 2006-12-14 2015-12-02 埃克塞利希斯股份有限公司 Methods of using MEK inhibitors
SI2412828T1 (en) 2007-03-13 2013-10-30 Amgen Inc. K-ras and B-raf mutations and anti-EGFr antibody therapy
WO2008120004A1 (en) 2007-04-02 2008-10-09 Astrazeneca Ab Combination of a mek- inhibitor and a b-raf inhibitor for the treatment of cancer
CA2694646C (en) 2007-07-30 2017-09-05 Ardea Biosciences, Inc. Combinations of mek inhibitors and raf kinase inhibitors and uses thereof
JP2011513329A (en) 2008-02-29 2011-04-28 アレイ バイオファーマ、インコーポレイテッド Imidazo [4,5-b] pyridine derivatives used as RAF inhibitory compounds
CA2716949A1 (en) 2008-02-29 2009-09-11 Array Biopharma Inc. N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer
CL2009000447A1 (en) 2008-02-29 2010-01-04 Array Biopharma Inc Y Genentech Inc Compounds derived from (1h-pyrrolo {2,3-b} pyridin-5-yl) -sulfonamido-substituted benzamide; preparation procedure; pharmaceutical composition; and its use in the treatment of cancer, through the inhibition of raf.
MX2010009411A (en) 2008-02-29 2010-11-30 Array Biopharma Inc Pyrazole [3, 4-b] pyridine raf inhibitors.
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
DE102008059206A1 (en) * 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmaceutical dosage form containing nifedipine or nisoldipine and an angiotensin II antagonist and / or a diuretic
EA031116B1 (en) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг PROPANE-1-SULFONIC ACID {3-[5-(4-CHLORO-PHENYL)-1H-PYRROLO[2,3-b]PYRIDINE-3-CARBONYL]-2,4-DIFLUORO-PHENYL}AMIDE CRYSTALLINE POLYMORPH FORMS
IN2012DN01403A (en) 2009-08-24 2015-06-05 Genentech Inc
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
EP2488184A4 (en) 2009-10-12 2013-04-24 Glaxosmithkline Llc Combination
US20110086837A1 (en) * 2009-10-12 2011-04-14 Genentech, Inc. Combinations of a pi3k inhibitor and a mek inhibitor
WO2011104694A2 (en) * 2010-02-26 2011-09-01 GAMMAGENETICS Sàrl Detection of braf v600e mutation by allele specific real time quantitative pcr (as-qpcr) using locked nucleic acids primers and beacon probes
AU2011224410B2 (en) 2010-03-09 2015-05-28 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
WO2012027716A1 (en) 2010-08-27 2012-03-01 Collabrx, Inc. Method to treat melanoma in braf inhibitor-resistant subjects
JP5837072B2 (en) * 2010-09-03 2015-12-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Formulations that use water-soluble antioxidants
JP2014505658A (en) 2010-11-05 2014-03-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ナンバー２、リミテッド How to treat cancer
AU2011329666A1 (en) 2010-11-19 2013-05-30 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment with BRaf inhibitor
EP2640860A4 (en) 2010-11-19 2014-06-04 Univ California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
US9295669B2 (en) * 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
TWI505828B (en) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 Novel pharmaceutical composition
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
WO2012145503A1 (en) 2011-04-21 2012-10-26 Novartis Ag Pharmaceutical combinations
US20130172375A1 (en) 2011-12-13 2013-07-04 Hoffmann-La Roche Inc. Pharmaceutical composition
US9216170B2 (en) 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
KR20210108502A (en) * 2012-08-17 2021-09-02 에프. 호프만-라 로슈 아게 Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
JP2016509045A (en) 2013-02-22 2016-03-24 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト How to treat cancer and prevent drug resistance

Also Published As

Publication number Publication date
LT2884979T (en) 2019-09-10
BR112015003418A2 (en) 2017-07-04
UA114923C2 (en) 2017-08-28
HUE044789T2 (en) 2019-11-28
DK2884979T3 (en) 2019-09-02
EA033573B1 (en) 2019-11-06
EA201590262A1 (en) 2015-06-30
WO2014027056A1 (en) 2014-02-20
CN110251512A (en) 2019-09-20
PT2884979T (en) 2019-09-04
US20140093568A1 (en) 2014-04-03
PE20151156A1 (en) 2015-08-19
US11087354B2 (en) 2021-08-10
KR20210108502A (en) 2021-09-02
CA2879252C (en) 2017-10-10
PH12015500186A1 (en) 2015-04-06
AU2013304021A1 (en) 2015-02-12
JP6335169B2 (en) 2018-05-30
KR20150038068A (en) 2015-04-08
KR20190057421A (en) 2019-05-28
CA2879252A1 (en) 2014-02-20
US11783366B2 (en) 2023-10-10
KR20170044759A (en) 2017-04-25
IL237065A0 (en) 2015-03-31
NZ744862A (en) 2019-06-28
CO7180225A2 (en) 2015-02-09
SI2884979T1 (en) 2019-10-30
MX2015002031A (en) 2015-06-05
PL2884979T3 (en) 2019-11-29
EP2884979A1 (en) 2015-06-24
HK1206605A1 (en) 2016-01-15
MY180613A (en) 2020-12-03
EP2884979B1 (en) 2019-06-26
CN104640545A (en) 2015-05-20
RS59113B1 (en) 2019-09-30
SG10201913359TA (en) 2020-02-27
ZA201500348B (en) 2019-07-31
HRP20191533T1 (en) 2019-11-29
JP2017160214A (en) 2017-09-14
KR20220165811A (en) 2022-12-15
CA2928396A1 (en) 2014-02-20
CL2015000345A1 (en) 2015-05-22
SG11201500582UA (en) 2015-04-29
SG10201708494QA (en) 2017-11-29
JP2015531763A (en) 2015-11-05
US20240046303A1 (en) 2024-02-08
US20220172244A1 (en) 2022-06-02
ES2743427T3 (en) 2020-02-19
IL237065B (en) 2020-07-30
AU2013304021B2 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
PH12015500186A1 (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafinib
TW200942552A (en) Combination therapy with c-Met and HER antagonists
MX2014002990A (en) Combination treatments comprising c-met antagonists and b-raf antagonists.
MX2020010535A (en) Methods of treating cancer.
PH12015500825B1 (en) Substituted benzene compounds
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
MX2013011922A (en) Substituted benzene compounds.
MX2015017485A (en) Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases.
EP2569014A4 (en) Treatment methods
IN2014DN09228A (en)
MX2015005963A (en) Heterocyclic glutaminase inhibitors.
JO3363B1 (en) Aryl- or heteroaryl-substituted benzene compounds
MX346147B (en) 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use.
MX366804B (en) R-spondin translocations and methods using the same.
TN2013000227A1 (en) Use of sigma ligands in bone cancer pain
TW201611843A (en) Methods of treatment with arginine deiminase
MX2014012477A (en) Pyrrolopyrazone inhibitors of tankyrase.
MY191932A (en) Chitosan-derived compositions
MX341020B (en) Human lactoferrin derived peptides and there use.
GB2528604A (en) Modulation of asymmetric proliferation
NZ735626A (en) Combination therapies for melanoma comprising administering cobimetinib and vemurafenib
GB2519004A (en) Quinone compounds and their uses for the treatment of cancer
EP2575766A4 (en) Novel pharmaceutical compounds

Legal Events

Date Code Title Description
GD Licence granted
FG Grant or registration